Last reviewed · How we verify
RUBELLA VIRUS, LIVE ATTENUATED
At a glance
| Generic name | RUBELLA VIRUS, LIVE ATTENUATED |
|---|---|
| Phase | FDA-approved |
| First approval | 2006 |
Approved indications
Common side effects
Key clinical trials
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (PHASE3)
- Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (PHASE3)
- Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RUBELLA VIRUS, LIVE ATTENUATED CI brief — competitive landscape report
- RUBELLA VIRUS, LIVE ATTENUATED updates RSS · CI watch RSS